Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alfacalcidol + etidronate
- Development stage
- Unknown
- Lead developer
- LEO Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of alfacalcidol (a vitamin D analog) and etidronate (a bisphosphonate). Alfacalcidol helps regulate calcium metabolism and promotes bone formation, while etidronate inhibits bone resorption by osteoclasts. This combination works synergistically to improve bone health through different mechanisms. The typical regimen involves intermittent cyclical etidronate (200 mg daily for 2 weeks every 3 months) combined with continuous alfacalcidol (1 μg daily).
- Other names
- cyclical etidronate combined with alfacalcidol
02
Targets
VDR (Vitamin D receptor)
Beyond the preview
Go deeper on alfacalcidol + etidronate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alfacalcidol + etidronate.